End Stage Kidney Disease (ESKD) or End Stage Renal Disease (ESRD), the fifth and last stage of Chronic Kidney Disease (CKD), is recognised as a major public health problem. It occurs where kidneys are no longer capable of sufficiently filtering waste products from the blood. With kidney function at less than 10 %, a kidney transplant or an external means of filtering is needed. The latter consists of either Haemodialysis (HD) or Peritoneal Dialysis (PD). Globally, we are seeing an increasing prevalence in ESRD. This is caused by an aging population in the west, socio-economic factors, increased hypertension, and growing diabetes and obesity epidemics. HD takes an average of 4 hours per treatment session and occurs 3 times a week while PD occurs 4 times a day with each exchange requiring 40 minutes on average. Most dialysis occurs in specific dialysis centres and hospitals, adding further time for travel. Non-compliance with treatment schedules are a particular issue with PD. This makes it difficult for doctors to calculate correct treatment plans as patients may not share this information with their doctor. Non-compliance can be as high as 53%, decreasing efficacy of the treatment leading to poorer health overall and speeds up rate of decline.
LiberDi revolutionises traditional Peritoneal Dialysis with LPPDS, a smart, real-time, patient-monitoring, truly portable device. It’s lightweight, easy to set up and allows patients to carry out their dialysis at home, at work or while travelling. LPPDS has UX at the very core of its design to ensure ease of use: smart automation, catheters and sterile connectors. The system consists of a patent-pending disposable that holds a smart peristaltic pump designed to improve adherence to protocol, and reduce human errors, while saving time via fluid flow rate and treatment management.